European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment
October 08 2019 - 7:30AM
Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company,
today announced that the European Patent Office granted a new
patent (#EP 2 929 015 B1) covering ALLOCETRATM, the company’s
immunotherapy product. This new patent adds intellectual property
protection, including methods, uses and pharmaceutical compositions
in the EU.
ALLOCETRA™ is a novel immunotherapy based on a unique mechanism
of action that targets life threatening diseases that are
defined as “unmet medical needs” such as preventing or
treating complications associated with bone marrow transplants
(“BMT”) and/or hematopoietic stem cell transplants (“HSCT); organ
dysfunction and acute multiple organ failure associated with sepsis
and enablement of an effective treatment of solid tumors via immune
checkpoint rebalancing.
ABOUT ENLIVEX
Enlivex is a clinical stage immunotherapy company, developing an
allogeneic drug pipeline for immune system rebalancing. Immune
system rebalancing is critical for the treatment of
life-threatening immune and inflammatory conditions which involve
an out of control immune system (e.g. Cytokine Release Syndrome)
and for which there are no approved treatments (unmet medical
needs), as well as solid tumors immune-checkpoint rebalancing. For
more information, visitwww.enlivex.com.
Safe Harbor Statement: This press release
contains forward-looking statements, which may be identified by
words such as “expects,” “plans,” “projects,” “will,” “may,”
“anticipates,” “believes,” “should,” “would”, “intends,”
“estimates,” “suggests,” “has the potential to” and other words of
similar meaning, including statements regarding the results of
current clinical studies and preclinical experiments and the
effectiveness of ALLOCETRATM programs, which are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that forward-looking
statements involve risks and uncertainties that may affect
Enlivex’s business and prospects, including the risks that Enlivex
may not succeed in generating any revenues or developing any
commercial products; that the products in development may fail, may
not achieve the expected results or effectiveness and/or may not
generate data that would support the approval or marketing of these
products for the indications being studied or for other
indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that
may cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the
results of clinical and other trials in animals. The results of
early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products
using the ALLOCETRATM product line could also be affected by a
number of other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors described
above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in
Enlivex’s filings with the Securities and Exchange Commission. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements,
except as required under applicable law.
ENLIVEX CONTACT:Shachar Shlosberger, CFOEnlivex Therapeutics,
Ltd.shachar@enlivex-pharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024